Novel Agents in the Treatment of Lung Cancer: New Approaches to First-Line Therapy
CME Monograph - October 2009
Overview
Results of important recent clinical studies of first-line EGFR TKI therapies, antibodies combined with chemotherapy, consolidation and up-front supportive care are creating the potential to change the paradigm for what constitutes appropriate first-line care for non–small cell lung cancer (NSCLC) patients. Medical professionals who work with lung cancer patients need to understand the results of these new studies assess their implications for the management of NSCLC and integrate this information into their practice of assessing, counseling and treating individual patients.
The program was directed by Thomas J. Lynch, Jr, MD, Director, Yale Cancer Center, Physician-in-Chief Smilow Cancer Center at Yale – New Haven, Connecticut.
Target Audience
This educational activity is intended for oncologists and other medical professionals who assess, treat, and counsel patients with lung cancer.
Companion CME Activity
A companion CME activity, Lung Cancer: Case Studies Assessing Novel Agents in First-Line Therapy, based on videotaped discussion of cases is available at First-Line Case Studies. The activity provides more in-depth information on this topic, featuring an overview by Thomas J. Lynch, Jr, MD, and discussion of 4 cases by the same program faculty that developed this activity. The activity offers up to 2 additional AMA PRA Category 1 Credits™.
Educational Grant Support
The program is supported by educational grants provided by Bristol-Myers Squibb and ImClone Systems Inc., Boehringer Ingelheim Pharmaceuticals, Inc., and Genentech.
Sponsorship
CME sponsorship and program management were provided by InforMEDical.
The online CME activity is effective February 2010 through January 2011.
